IP Library › Granted Patent US 11,648,318
Granted Patent B2
US 11,648,318 · App. 17/811,396 · Granted May 16, 2023

Anti-transferrin receptor (TFR) antibody and uses thereof

Inventors: Romesh R. Subramanian (Framingham, MA); Mohammed T. Qatanani (Waltham, MA); Timothy Weeden (Waltham, MA); Cody A. Desjardins (Waltham, MA); Brendan Quinn (Boston, MA); John Najim (Waltham, MA)
Assignee: Dyne Therapeutics, Inc.
A61K47/6849A61K47/6807A61K47/6811A61K47/6889A61P21/00C07K16/2881A61K2039/505A61K2039/545C07K2317/24C07K2317/55C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,648,318
App. No.
17/811,396
Granted
May 16, 2023
Kind
B2
Abstract

Aspects of the disclosure relate to antibodies that bind to transferrin receptor (e.g., transferrin receptor 1) and complexes comprising the antibody covalently linked to a molecular payload. Methods of using the antibodies are also provided.

Claims (9)

1. A composition comprising a plurality of anti-transferrin receptor (TfR) antibodies, wherein each anti-TfR antibody is a Fab comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 101 and a light chain comprising the amino acid sequence of SEQ ID NO: 90.

2. The composition of claim 1 , wherein the heavy chain of anti-TfR antibodies of the composition comprises an N-terminal pyroglutamate.

3. The composition of claim 1 , wherein the composition is an aqueous solution.

4. The composition of claim 1 , wherein the composition is lyophilized.

5. The composition of claim 1 , wherein the composition is present in a container.

6. The composition of claim 1 , wherein the composition is present in a column.

7. The composition of claim 1 , wherein the composition is present in a subject.

8. The composition of claim 1 , wherein the composition is present in a cell.

9. The composition of claim 1 , wherein the antibodies are bound to a solid support.

Assignments (2)
SECURITY INTEREST Recorded Jun 27, 2025
From: DYNE THERAPEUTICS, INC.
To: HERCULES CAPITAL, INC., AS AGENT
Reel/Frame 071777/0300 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 1, 2022
From: SUBRAMANIAN, ROMESH R.; QATANANI, MOHAMMED T.; WEEDEN, TIMOTHY; DESJARDINS, CODY A.; NAJIM, JOHN; QUINN, BRENDAN
To: DYNE THERAPEUTICS, INC.
Reel/Frame 061937/0853 →
Continuity (2)
Provisional Application 63220043 · Jul 9, 2021
Related Publication 20230044278A1 · Feb 9, 2023
Cited By (21)
US 12,239,716 US 12,239,717 US 12,263,225 US 12,280,122 US 12,319,743 US 12,325,753 US 12,329,824 US 12,329,825 US 12,357,703 US 12,370,264 US 12,397,062 US 12,403,203 US 12,428,487 US 12,440,574 US 12,440,575 US 12,460,011 US 12,478,687 US 12,496,352 US 12,624,120 US 12,662,545 US 12,697,394